
News|Articles|June 1, 2004
Switching from tamoxifen to exemestane could reduce breast cancer recurrence
Disease-free survival in postmenopausal women with primary breast cancer significantly improved when tamoxifen monotherapy treatment was switched to exemestane therapy after 2-3 years, according to a study published in the New England Journal of Medicine. The existing treatment paradigm calls for tamoxifen, an estrogen-receptor modulator, to be taken alone for all 5 years, but some patients have experienced relapse.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Study finds gaps in recommended cardiac amyloidosis testing
2
Zucker School of Medicine receives $1.8 million grant to train physician-scientists
3
Survodutide reduces liver fat in 84% of patients in phase 3 trial
4
ctDNA in the de-escalation of breast cancer therapy. A puzzle not solved.
5



































